Long-Term Treatment of Angina Pectoris with Bisoprolol or Atenolol in Patients with Chronic Obstructive Bronchitis

Dorow, P.; Thalhofer, S.; Bethge, H.; Disselhoff, G.; Wagner, G

doi:10.1097/00005344-199006165-00008

Cited by 15 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in one study that explored the long-term effects of BBs, FEV 1 declined significantly over six months by approximately 200 ml [26]. Whether patients with asthma -COPD overlap syndrome (ACOS) might be at higher risk for BB-induced bronchoconstriction should be carefully investigated in future safety studies.…”

Section: Bbs In Patients With Copd: Current Questionsmentioning

confidence: 99%

Role of beta-blockers in patients with COPD: current perspective

Malerba

Montuschi

Radaeli

et al. 2015

Drug Discovery Today

View full text Add to dashboard Cite

Section: Bbs In Patients With Copd: Current Questionsmentioning

confidence: 99%

Role of beta-blockers in patients with COPD: current perspective

Malerba

Montuschi

Radaeli

et al. 2015

Drug Discovery Today

View full text Add to dashboard Cite

“…The efficacy of 10 mg of bisoprolol was comparable to that of 100 mg of atenolol (32). Facultative dose increases from 5 to 10 mg of bisoprolol and from 50 to 100 mg of atenolol were not necessary (7). This finding can also be seen as a proof of efficacy and equipotency of 5 mg of bisoprolol in relation to 50 mg of atenolol.…”

Section: Angina Pectoris Attack Rate and Nitroglycerin Consumptionmentioning

confidence: 53%

“…Bisoprolol has a therapeutic dose ratio of 1:lO in relation to atenolol (7,32). The predictions derived from the clinical pharmacology study in human volunteers (51)(52)(53)(54) are thus confirmed.…”

Section: Results During Exercise Testsmentioning

confidence: 99%

Bisoprolol in Angina Pectoris

Bethge¹,

Léopold²,

Wagner³

1991

Cardiovascular Drug Reviews

Self Cite

View full text Add to dashboard Cite

The treatment of angina pectoris caused by coronary artery disease with @-blockers is generally accepted. P-Blockers competitively inhibit the effect of endogenous catecholamines at @-receptors. Reduction in the positive chronotropic and positive inotropic effect of the catecholamines on the myocardium results in a decrease in the myocardial oxygen demand in patients with coronary artery disease, in particular in situations where there is frequently increased catecholamine release. The reduction in the positive bathmotropic effect of the catecholamines can probably explain the antiarrhythmic effect of P-blockers and their protective effect against acute cardiac death.Numerous P-blockers have been introduced into therapy in the last 20 years. Their mode of action in angina pectoris does not differ fundamentally between substances. However, additional pharmacodynamic and pharmacokinetic properties of the individual P-blockers are often of importance in practical therapy: (a) For certain therapeutic aims, for instance reinfarction prophylaxis, P-blockers without intrinsic sympathomimetic activity (ISA) are preferred. (b) For as low-risk treatment as possible of patients with often nondefinitively identified concomitant diseases, such as chronic obstructive bronchitis, a P-blocker with pronounced PI selectivity is desirable. It does not impair the effect of the frequently prescribed P,-agonists, thus having an advantage over nonselective P-blockers where the bronchodilatory effect of the P,-agonist is impaired. (c) To permit once-a-day treatment, longer-acting P-blockers are preferred in all indications for @-blocker treatment, i.e., particularly in the case of angina pectoris. (d) For pharmacokinetically rational @-blocker treatment of patients with specific pathophysiological conditions, such as impaired renal or hepatic function, a P-blocker that can be cleared both renally and metabolically (hepatically) is preferred.Bisoprolol is a @-blocker without ISA (18,24,30) with pronounced PI selectivity

show abstract

“…FEV 1 declined significantly (~0.2 l) over 6 months in both treatment arms. Although lacking a concurrent placebo group, lung function parameters normalized during the placebo washout periods, suggesting beta-blockade could have caused bronchoconstriction [84].…”

Section: Adrenergic Blockadementioning

confidence: 98%

“…Patients remained free of adverse respiratory effects and FEV 1 was unchanged [83]. In a randomized, doubleblind, crossover trial, 40 CAD patients with mild COPD and significant reversibility received either bisoprolol 5 mg or atenolol 50 mg [84]. FEV 1 declined significantly (~0.2 l) over 6 months in both treatment arms.…”

Section: Adrenergic Blockadementioning

confidence: 99%

Beta-blockers in patients with chronic obstructive disease and coexistent cardiac illnesses

Álvarez-Sala

Miguel-Díez

2015

COPD Res Pract

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease is prevalent condition commonly associated with cardiovascular diseases. When both are combined the prognosis of the patient worsens. One cornerstone therapy for most cardiac diseases is beta-blockade, however concerns about its potential harmful effects on airways function often restrains their use in patients with COPD and coexistent cardiac diseases. While selective beta 1 adrenergic blockers seem to have a better safety profile, other non-selective beta-blockers can be securely utilized in stable COPD patients with no or little reactivity when they are indispensable and used with caution. Evidence provided by post hoc analysis of clinical trials and large observational studies suggests a beneficial effect of beta-blockers on mortality and exacerbations in mild to moderate COPD patients. Benefits are less obvious in severe COPD. Studies on the actual use of beta-blockers suggest that many cardiac patients with COPD (or vice versa) who can benefit from beta-blocker utilization do not receive such medication as it is recommended in the guidelines because of die-hard, not justified in most cases, concerns on safety.

show abstract

Long-Term Treatment of Angina Pectoris with Bisoprolol or Atenolol in Patients with Chronic Obstructive Bronchitis

Cited by 15 publications

References 0 publications

Role of beta-blockers in patients with COPD: current perspective

Role of beta-blockers in patients with COPD: current perspective

Bisoprolol in Angina Pectoris

Beta-blockers in patients with chronic obstructive disease and coexistent cardiac illnesses

Contact Info

Product

Resources

About